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Summary 
The availability of large quantities of highly purified recombinant interleukin 11 (rhulL-11) has 
allowed us to investigate the effects of rhuIbll on sheep red blood cell (SRBC)-specific antibody 
responses in the routine system.  The results showed that rhuII~11 was effective in enhancing 
the generation of mouse spleen SRBC-specific  plaque-forming cells (PFC) in the in vitro cell 
culture system in a dose-dependent manner. These effects of rhuIL-11 were abrogated completely 
by the addition of anti-rhulbll antibody, but not by the addition of preimmunized rabbit serum. 
Cell-depletion studies revealed that L3T4 (CD4) + T  cells, but not Lyt-2 (CD8) + T  cells, are 
required in the rhuIL-11-stimulated augmentation of SRBC-specific antibody responses. The effects 
of rhulL-11 on the SRBC-specific  antibody responses  in vivo were also examined. Rhulbll 
administration to normal C3H/HeJ mice resulted in a dose-dependent increase in the number 
of spleen SRBC-specific PFC as well as serum SRBC-specific antibody titer in both the primary 
and secondary immune responses. In mice immunosuppressed by cyclophosphamide treatment, 
rhuIbll administration siguificantly augmented the number of spleen SRBC-specific  PFC as 
well as serum SRBC-specific antibody titer when compared with the cyclophosphamide-treated 
mice without II.,11 treatment. These results demonstrated that IL,11 is a novel cytokine involved 
in modulating antigen-specific  antibody responses  in vitro as well as in vivo. 
G 
rowth and differentiation of B lymphocytes are regu- 
lated at least in part by many soluble factors called cyto- 
kines that are produced by a variety of cells (1-3).  Although 
the exact number of cytokines and the precise mechanisms of 
cytokine action involved in this process are still under inten- 
sive investigation, a number of cytokines such as II:2 (4-6), 
IL4 (7), Ib5 (8, 9), Ib6 (5, 6, 10, 11), IFN-,y (7, 12), and Ibl0 
(13) have been implicated to play an important role in modulat- 
ing B cell activation, proliferation, and/or differentiation. 
Recently, a new cytokine designated as IL-11 was identified 
in medium conditioned by a ceU line derived from primate 
bone marrow stromal cells (14). The cDNA encoding pri- 
mate IL-11 was cloned by expression cloning method based 
on the ability of this cytokine to stimulate the proliferation 
of an Ib6-dependent mouse plasmacytoma cell line, Tl165 
(14). The human homologue  of primate IL,11 was subsequently 
cloned and expressed in mammalian cells (14). Initial studies 
have  shown that  Ibll  is  able  to increase  the number of 
antibody-forming cells in murine spleen cell cultures and to 
augment Ib3-dependent development of megakaryocyte colo- 
nies in both human and mouse bone marrow cultures. Re- 
cent studies have also shown that recombinant human IL-11 
(rhulL-11), like IL-6, can bring the pluripotent stem calls out 
of the Go stage of the cell cycle to respond to intermediate 
or late-acting growth factors such as IL-3 or granulocyte/mac- 
rophage CSF  (15). These results imply that  rhuIbll 1 is 
likely to be a multifunctional mediator in the complicated 
cytokine network. 
Since many biological activities  of Ibll overlapped with 
those of Ib6, and IL-6 has been shown to play an important 
role in modulating immune responses,  we speculated  that 
Ibll may also contribute to the immunologic events critical 
to the host defense system. As a first step of understanding 
the role of ILl1 in regulating immune responses, we tested 
the effects of rhuIL-11 on antigen (Ag)-specific antibody re- 
sponses in vitro and in vivo. The results demonstrated that 
Ibll significantly enhanced in vitro Ag-specific antibody re- 
sponses and augmented Ag-specific antibody responses in both 
normal mice and mice immunosuppressed  by cyclophospha- 
mide (CYC) treatment. 
1 Abbreviations  used in this paper:  Ag, antigen; CYC, cyclophosphamide; 
PFC, plaque-forming cells; rhulL-11, recombinant human interleukin 11. 
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M~:~  C57BL/6J and C3H/HeJ female mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME). Mice aged 8-12 wk 
were used in all the experiments. 
RhulL-11.  Rhulb11 produced in Esckerickia coli and purified to 
homogeneity was  obtained from Genetic Institute (Cambridge, 
M_A). Purified rhulL-11 had a specific activity of 1.8  x  106 U/mg 
by Tl165 cell proliferation assay (14) and contained <1.25 ng en- 
dotoxin/mg protein. 
Antibodies.  Anti-Thy-l.2 mAb, anti-L3T4 mAb, and anti-Lyt-2 
mAb were purchased from Cedarlane Lab (Ontario, Canada).  Poly- 
clonal rabbit anti-rhulL-11 antiserum was a generous gift from Dr. 
Ed Alderman (Genetics Institute). 
Cell Preparation.  To deplete CD3 +,  CD4 +,  or CD8 + cells, 
routine spleen cells were incubated with anti-Thy-l.2 mAb, anti- 
L3T4 mAb, or anti-Lyt-2 mAb in RPMI 1640 supplemented with 
0.5% BSA, 100 U/ml penicillin, 100 #g/ml streptomycin, 2 mM 
r-glutamine, and 5  x  10 -5 M  B-mercaptoethanol (hereafter re- 
ferred to as treated medium). After a 1-h incubation at 4~  cells 
were washed three times in treated medium and resuspended in 
treated medium containing 1:15 dilution of rabbit complement 
(Cedarlane Lab). After incubation at 37~  for 40 min with com- 
plement, cells were washed three times in treated medium and 
resuspended in IMDM (Sigma Chemical Co., St. Louis, MO) sup- 
plemented with 10% FCS (Hyclone, Logan, UT), 100 U/ml peni- 
cillin,  100  #g/ml  streptomycin,  2  mM  r-glutamine  and  5  x 
10 -s  M  ~-mercaptoethanol  (hereafter  referred  to  as  complete 
culture medium). 
Assay for SRBC-Specific PFC In  Vitra  Untreated or treated 
spleen cells (2  x  106) were cultured in 24-well flat-bottomed plates 
(Becton Dickinson & Co., Lincoln Park,  NJ) in a volume of 0.5 
ml of complete culture medium with 4  x  10  s to 106 SRBC in 
the presence or absence of various concentrations of rhull.~11. The 
plates  were placed on a rocker platform at 7-10 complete cycles 
per rain (16) and incubated for 4 or 5 d at 37~  in a humidified 
atmosphere of 7% 02,  10% CO2,  and 83%  N2. At the end of 
culture period, cells were collected, washed once with RPMI 1640 
(Sigma Chemical Co.), and resuspended in RPM11640 supplemented 
with 2 mM t-glutamine. The number of SRBC-specific plaque- 
forming cells (PFC) per 10  + spleen cells was identified with petri- 
dish plaque assay as described  by Dresser (17). 
Determination of SRBC-Specific PFC and Antibody Titer In Vivo. 
SRBC were washed three times, resuspended in pyrogen-free PBS, 
and  inoculated intraperitoneally at  2  x  106 (for secondary re- 
sponse) or 4  x  107 (for primary response)/0.2 ml/mouse. On the 
same day of antigen inoculation, groups of three mice received in- 
jections twice daily (once intraperitoneally, once subcutaneously) 
with 0.2 ml/mouse of 2.5% syngeneic mouse serum in PBS con- 
taining various concentrations of rhulb11 for 6 d. Control mice 
received the same volume of solution without IL-11. At 7 d, mice 
were killed,  spleen cells and serum collected, and SRBC-specific 
PFC were assayed as described above. Anti-SRBC-specific antibody 
titer in serum was measured by a hemagglutination test (6). Briefly, 
50/~1 of a twofold serial dilution of mouse immune serum was 
mixed with 50 #1 of 1% SRBC suspension  containing 1% BSA 
in PBS. The agglutination titer was determined after a 6-h incuba- 
tion at 4~  as the reciprocal of the highest dilution giving distinct 
agglutination. 
CYC Treatment.  CYC (Sigma)  was dissolved in pyrogen-free 
saline and injected intraperitoneally at a dose of 200 mg/kg body 
weight. 4 h after CYC treatment, each mouse received 4  x  107 
SRBC intraperitoneally. RhulL-11 (1-/~g/injection, once intraperito- 
neaUy, once subcutaneously) or control solution treatment began 
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the next day and continued for the duration of the experiment. 
At various times, groups of three mice were killed and splenic PFC 
as well as serum antibody titer were determined as described above. 
Measurement of Total  lg Concentration  in Serum.  The total amount 
of Ig in mouse serum was determined by ELISA as described  by 
Luzuy et al. (18). 
Statistical Analysis.  Statistical  significance was assessed by the 
Student's t test. Probabilities were calculated by two-tailed analysis. 
Results and Discussion 
Effect of rhulI.,ll on the Primary Immune Response to SRBC. 
We examined the effect of purified rhulL-11 on the primary 
immune response to SRBC of spleen cells from C57BL/6J 
mice. Mouse spleen cells were cultured with SRBC in the 
presence of various concentrations of rhulL-11.  Specific di- 
rect PFC were counted on day 5, previously determined to 
be the optimal  period for the PFC  responses  (our unpub- 
lished results).  As shown in Fig.  1,  rhulL-11 induced  IgM 
PFC response in a dose-dependent manner. The addition of 
as low as 1 U/ml rhulbll could increase IgM PFC 3.3-fold. 
At the concentration of 500 U/ml, rhulL-11 increased IgM 
PFC 6.7-fold. These results suggested that rhulL-11, like I1:6 
(6),  is a  strong inducer of SRBC-specific PFC in vitro.  In 
addition,  the  kinetic  studies  showed  that  the  addition  of 
rhulL-11 48 h after the initiation of spleen cell culture failed 
to increase Ag-specific PFC (data not shown), suggesting that 
rhulb11,  unlike IL-6 (6),  has to be added at an early stage 
of cell culture in  order to elevate Ag-specific PFC. 
Effect of rhulbll  on the Immune Response to SRBC  Using 
Spleen Cells from SRBC-Primed Mice.  As rhulb11 is an effec- 
tive enhancer of SRBC-specific IgM PFC in the primary im- 
mune response, we next examined whether rhulbll augments 
the in vitro response to spleen cell primed with SRBC Ag 
in vivo. Mice were immunized intraperitoneally with 4  x 
107 SRBC/mouse. 2 d after immunization, spleen cells were 
removed and restimulated in vitro with SRBC in the pres- 
ence of rhulI~11. On day 4 (previously determined to be the 
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Figure 1.  Effect  of rhullr  on primary immune response to SRBC 
in vitro. C57BL/6J mouse spleen cells (2 x  106/well  in 0.5 ml medium) 
were cultured with 106 SRBC in the presence of various concentrations 
of rhulL-11 in 24-weU  plates as described  in Materials and Methods. SRBC- 
specific direct PFC were counted on day 5 of the culture. The data are 
the arithmetic means (_+ SD) of duplicate cultures. Three additional ex- 
periments showed similar results. The spleen cells cultured with I1.,11 in 
absence of SRBC did not show any SRBC-specific PFC. 
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Figure  2. 
sponse to SRBC in vitro. C57BL/6J mice were injected with 4  x  107 
SRBC/mouse i.p. 2 d after immunization, spleen cells (2  x  106/well in 
0.5 ml medium) were restimulated with 4  ￿  105 SRBC in the presence 
of various  concentrations of rhulLll.  SR.BC-specific direct PFC were 
counted on day 4 of the culture. The data are the arithmetic mean (_+ SD) 
of duplicate cultures. Three additional experiments showed similar results. 
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Effect of rhulbll on in vivo SRBC-primed spleen cell re- 
optimal period for the PFC response),  SRBC-specific  PFC 
were assayed. It was demonstrated that rhulL-11 augmented 
IgM PFC in a dose-dependent  manner when spleen cells from 
SRBC-immunized mice were used (Fig. 2). However, SRBC- 
primed spleen cells cultured in vitro without SRBC restimu- 
lation failed to respond to rhulL-11 in eliciting the SRBC- 
specific PFC response (data not shown). These results indi- 
cated that rhulbll  could not induce the differentiation of 
antigen-primed B cells to become antibody-producing cells 
without antigen restimulation. The kinetic studies using in 
vivo primed spleen cell culture system showed that rhulL-11, 
unlike Ib6 (6), has to be added at an early stage of cell cul- 
ture in order to significantly augment Ag-specific  PFC. 
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Figure 3.  Neutralization of rhulL-11-induced  enhancement of PFC in 
primary immune response to SRBC by anti-rhulL-11 antibody. C57BL/6J 
mouse spleen cells (2  x  106/well in 0.5 ml medium) were cultured with 
106 SRBC in the presence of indicated amounts of rhulL-11 (~--N-~. or 
rhulL-11 neutralized by incubation with 50 neutralization units of anti- 
rhulL-11 antibody (~5i~3) or preimmunized rabbit serum (F-/77) at 37~ 
for 2 h. SRBC-specific direct PFC were counted on day 5 of the culture. 
The data are expressed as the mean (• SD) of duplicate cultures. Represen- 
tative results  of two separate experiments are shown. 
Abrogation of  rhulL11-induced  Augmentation of  SRBC-specific 
PFC Responses by anti-rhull_,11 Antibody.  To  demonstrate 
rhulbll  as an enhancer of SR.BC-spedfic PFC,  the effect of 
anti-rhulL-11  antibody on the rhulL-11-induced  augmenta- 
tion  of SILBC-specific PFC  was  examined.  Addition of 50 
neutralization  units of anti-rhulL-11  antibody totally abol- 
ished the capacity of rhulL-11  to increase the production  of 
SP,  BC-specific PFC  (Fig.  3),  whereas  the  addition of same 
concentration  of preimmunized  rabbit  serum  had  no  effect 
Figure 4.  Effect of T  cell depletion on rhulL-11-induced augmentation of PFC response  to SRBC in vitro. 2  x  106/well of spleen cells (~i~) 
or spleen cells treated with anti-Thy-l.2 mAb (..~ffT/~., anti-Lyt-2 mAb (~-3~. or anti-L3T4 mAb (~)  plus complement, as described in Materials 
and Methods, were cultured with 106 SRBC for 5 d in primary response (,4),  or with 4  x  10  s SRBC for 4 d in in vivo SRBC-primed spleen cell 
response  (B). SRBC-specific  direct PFC were determined and the mean (•  of duplicate cultures is shown.  Two additional experiments showed 
similar pattern. 
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production in CYC-treated  mice. 4 h after CYC treatment,  C3H/HeJ 
mice were immunized with 4  x  107 SRBC i.p. On the next day, mice 
received IL-11 (~ or control solution (~)  injection for the duration 
of the experiment as described in Materials and Methods. (-4) The number 
of spleen SRBC-specific direct PFC was determined  and the results are 
the arithmetic means of three individually assayed  mice per group for each 
time point. CYC-treated mice with IL-11  injection had significantly higher 
number of spleen SRBC-specific PFC when compared with CYC-treated 
mice without IL-11 treatment (day 3, p < 0.02; day 5, p <  0.02; day 7, 
p <  0.01; day 12, p  <  0.01; day 18, F <  0.02).  (B) Sera obtained from 
three mice per group were pooled, and anti-SRBC antibody titer was mea- 
sured by hemagglutination test as described in Materials and Methods. 
The data are expressed as the stimulation  index (defined as the anti-SRBC 
titer in contrbl mice or in IL,11-treated  mice/anti-SRBC titer in day-3  control 
mice). 
Figure 5.  Effect  of in vivo administration  of rhulb11 on the primary 
and secondary  responses.  (,4)  Role  of rhuIb11  in primary response. 
C3H/HeJ mice were inoculated with 4  x  10: SKBC/mouse i.p. at day 
0, and injected with indicated amounts of rhuIL-11 twice daily (once in- 
traperitoneally, once subcutaneously) for 6 d. At day 7, mouse spleen cells 
were assayed for SRBC-specific direct PFC as described in Materials and 
Methods. The data are the arithmetic  mean (+SD) of three individually 
assayed mice per group. Three additional experiments showed similar results. 
(B) Role of rhuIL-11 in secondary response. C3H/HeJ mice were injected 
with 4  x  107 SRBC/mouse i.p. 15 d after the first injection, mice were 
reinjected with 2  x  106 SRBC/mouse  i.p. These mice were then injected 
with rhuIb11 as indicated in A. At day 7, mouse spleen cells were assayed 
for SRBC-specilic  direct ~) and indirect (~7~1)..  PFC. The data are the 
arithmetic means (• SD) of three individually assayed  mice per group. Two 
additional experiments showed similar results. (C) Role of  rhuIL-11  in anti- 
SRBC antibody production in primary ~) and secondary (~ re- 
sponse. Mice sera were obtained from the primary and secondary response 
to SRBC in vivo as indicated above. Serum anti-SRBC-specific antibody 
titers were then measured by hemagghtination  test as described  in Materials 
and Methods. The data expressed as stimulation  index (defined as the anti- 
SRBC titer in treated mice/anti-SRBC titer in control mice) are the arith- 
metic means of three individually assayed mice per group. Two additional 
experiments showed similar results. 
on  the  enhancement  of SRBC-specific  PFC  response by 
rhuIb11. 
Effect of Depletion of T Cells  from Spleen Cells on rhull_,11 
Induced  Enhancement  of  the PFC Response.  To understand what 
cell populations in the spleen were required for the augmen- 
tation of the production of the SRBC-specific PFC by rhuII.-11, 
we tested the effect of T cell depletion on the IL-11-induced 
enhancement of SRBC-specific  PFC.  As shown in Fig. 4, 
depletions  of Thy-l.2 +  or  L3T4 +  cells  dramatically de- 
creased the rhulbll-induced enhancement of SRBC-specific 
PFC response using spleen cells primed with SRBC in vitro 
or in vivo.  The depletion  of Lyt-2 + T  cells did not affect 
the enhancement of PFC by rhulL-11. 
Effect of  rhulI.,I1 Administration on the Primary and Secondary 
Antibody Response in Normal Mice.  Since rhuIL-11 enhances 
Ag-specific  antibody  responses in vitro,  we next examined 
whether the administration of rhuIL-11 has similar effects in 
vivo. As shown in Fig. 5, A and C, administration of rhuIL- 
11  enhanced SRBC-specific  PFC response and anti-SRBC 
antibody  titer in a dose-dependent  manner in the primary 
immune response. At the concentration  of 4/~g/mouse/d, 
rhuIb11 increased  SRBC-specific PFC 5.2-fold and anti-SRBC 
antibody titer 7.5-fold, respectively. In the secondary immune 
response, mice were reinjected with 2  x  10  6 SRBC/mouse 
i.p.  15 d after the first injection of 4  x  10  ~ SRBC/mouse. 
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body titer were determined as described in Materials and 
Methods. It was found that rhuIL-11 strongly enhanced the 
Ag-specific antibody response in a dose-dependent fashion 
(Fig.  5, B and C). At the concentration of 4/zg/mouse/d, 
rhuIb11 increased SRBC-specific IgM PFC eight- and IgG 
PFC fourfold, and serum SRBC-specific antibody titer 10- 
fold, respectively. These results are comparable with the results 
obtained in the II.-6 system (6). However, the effects of IL-11 
on Ag-specific antibody responses in the primary response 
in vivo (Fig.  5, A  and C) may be different from those of 
Ib6 (6) and other cytokines. Both Ibl (19) and IL-6 (6) have 
been suggested to act directly on B cells and T cells. TNF-c~ 
(20) may affect on T cells, and ID3 (21) possibly acts on ac- 
cessory cells. Ibll may not directly affect B cells as evidenced 
by the in vitro studies. Whether IL-11 has direct effects on 
T  cells or accessory cells remains to be clarified. 
We  also  observed  that  administration  of rhullr  (4 
/~g/mouse/d for 6 d) did not significantly enhance the SRBC- 
specific PFC response or increase the total Ig content in mice 
that did not receive a secondary SRBC injection when com- 
pared with the control. Furthermore, SRBC-specific PFC in 
spleen  and  total  Ig  concentration  in  serum  were  not 
significantly enhanced by the administration of rhulbll into 
normal mice without Ag stimulation. These results demon- 
strated that rhulL-11 is not a polyclonal activator under our 
experimental conditions. However, we do not rule out the 
possibility that IDll may be a polyclonal activator at very 
high concentration since it has been reported that II.-6 is a 
very effective  polyclonal activator in vivo when tested at high 
concentration (22, 23). These questions will be addressed by 
using the II.,11 transgenic mouse model. 
Effect of rhulLll  Administration  on Restoration of Impaired 
Antibody Responses in CYC-treated Mice.  In addition to its 
ability to augment in vivo Ag-specific antibody response in 
normal mice, we also assessed the ability of rhulb11 to stimu- 
late the regeneration of Ag-specific antibody-forming cells 
in C3H/HeJ mice with CYC-induced lymphopenia. As shown 
in Fig. 6, A  and B, the spleen SRBC-specific PFC response 
and serum anti-SRBC antibody titer of the CYC-treated mice 
that received rhull.-11  injection were significantly enhanced 
at all time points when compared with the control CYC- 
treated mice. For example, CYC-treated mice with IDll ad- 
ministration at day 12 had 4.5-fold higher spleen SRBC-specific 
PFC and sixfold higher serum anti-SRBC antibody titer than 
control mice without II.-11 injection. This result suggests 
that  rhulL.11  may play an  important  role in  stimulating 
the recovery of impaired Ag-specific antibody response in 
CYC-treated mice and Ibll may have important therapeutic 
potential  specifically  to  stimulate  the regeneration of de- 
creased Ag-specific humoral immune responses induced by 
CYC  treatment. 
The major concern in these in vivo experiments is the pos- 
sible role of contaminating endotoxin in the Ag-specific an- 
tibody responses.  RhulL-11 used in these studies contained 
<1.25 ng endotoxin/mg protein of rhulL-11. This very low 
concentration of endotoxin did not affect the Ag-specific hu- 
moral immune responses in the endotoxin-resistant C3H/HeJ 
mice. Therefore, the possibility that endotoxin contaminant 
might account for the observed rhulL-11 effect in increasing 
Ag-specific antibody responses in vivo can be reasonably ex- 
cluded. 
In conclusion, the results presented here demonstrated that 
rhulb11 is a novel cytokine involved in modulating Ag-speciflc 
antibody production in vivo and in vitro in normal mice. 
In addition, administration of I1.-11 into mice after chemical- 
induced lymphopenia significantly stimulates the reconstitu- 
tion of decreased Ag-specific antibody-forming cells in CYC- 
treated C3H/HeJ mice. Although the mechanism by which 
IDll exerts its action in vivo is not clear at the present time, 
these data suggest that rhulL-11  may be potentially useful 
as an therapeutic agent in enhancing humoral immune re- 
sponse under certain clinical situations where accelerated lym- 
phoid functions might be beneficial. 
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